, Tracking Stock Market Picks
Enter Symbol:
Talecris Biotherapeutics (TLCR) [hlAlert]

up 29.72 %

Talecris Biotherapeutics (TLCR) rated Buy with price target $30 by BWS Financial

Posted on: Tuesday,  Jan 5, 2010  10:25 AM ET by BWS Financial

BWS Financial rated Buy Talecris Biotherapeutics (TLCR) on 01/05/2010, when the stock price was $22.20. Since then,
Talecris Biotherapeutics has gained 29.73% as of 05/31/2011's recent price of $28.80.
If you would have followed this BWS Financial's recommendation on TLCR, you would have gained 29.72% of your investment in 511 days.

Talecris Biotherapeutics Holdings Corp. is a biopharmaceutical company that is a producer and marketer of plasma-derived protein therapies in the world. The Company develops, produces, markets and distributes therapies that help people suffering from conditions, such as immune deficiency disorders, alpha-1 antitrypsin (AAT) deficiency, infectious diseases, hemophilia and severe burns. The Company?s largest product, Gamunex Immune Globulin Intravenous (Human), is one of the products in the intravenous immune globulin (IGIV) market. Its second largest product, Prolastin Alpha 1 Proteinase Inhibitor (Human), was granted orphan drug status and has a 71% share of sales in the United States, a 78% share of sales in the European Union and brand recognition within the alpha-1 proteinase inhibitor (A1PI) category. In June 2007, it acquired three additional plasma collection centers from International BioResources, L.L.C. (IBR).

· BWS Financial is a Los Angeles based independent stock research firm, which focuses primarily on undervalued companies with little or no street coverage, within the biotechnology, healthcare and technology industries. · BWS Financial focuses on companies that hold much potential in their industries, either through their product pipeline or technological innovations. · BWS Financial’s strategy is not to only specialize in a particular group of stocks, but to also provide investors with insight into other ideas where there is considerable misvaluation.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/5/2010 10:25 AM Buy
22.20 30.00
as of 12/31/2010
1 Week up  3.28 %
1 Month up  10.04 %
3 Months up  4.37 %
1 YTD up  7.56 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy